MEGAN GREEN: Open Payments
NPI 1548592355 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$799 in 50 payments from 18 companies in 2025. Trend: 2023 $1,014 · 2024 $821 · 2025 $799
Food & beverage: $799
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $163 |
| Lilly USA, LLC | 14 | $143 |
| Novo Nordisk Inc | 6 | $106 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| PFIZER INC. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
Products named: MOUNJARO, JARDIANCE, Rybelsus, VRAYLAR, QULIPTA, REXULTI, XIFAXAN, GEMTESA.
Industry payments across TX — which companies pay providers there.
